Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304).
Conduit C, Inderjeeth AJ, Allen R, Martin AJ, Parulekar W, Mulroe E, McJannett M, Zielinski RR, Thomson A, Tan TH, Sandhu SK, Reaume MN, Pook DW, North SA, Marx GM, Joshua A, Horvath L, McDermott R, Chowdhury S, Chi KN, Zhang AY, Stockler MR, Davis ID, Sweeney CJ; ANZUP Cancer Trials Group.
Conduit C, et al. Among authors: zhang ay.
Future Oncol. 2025 Jan 17:1-10. doi: 10.1080/14796694.2024.2440277. Online ahead of print.
Future Oncol. 2025.
PMID: 39819293